Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Endocr Relat Cancer. 2022 Sep 14;29(11):R173–R190. doi: 10.1530/ERC-22-0129

Figure 1: Overview of the MAPK and AKT signaling pathways.

Figure 1:

The main protein kinases driving these pathways are depicted. Kinase inhibitors that are presently FDA-approved for thyroid cancers are highlighted.